Nexcella's NXC-201 trial stops enrolling after a 95% response rate in AL amyloidosis
NEXICART-2 closed enrollment at 45 patients months after Immix reported a 19-of-20 complete response rate, setting up a December primary completion in a disease with no approved cell therapy.
Executive Summary
- Nexcella closed enrollment in its lead CAR-T trial for AL amyloidosis, moving the study to Active, not recruiting after lifting its enrollment target modestly, a routine step toward the trial's primary completion rather than a sign of distress.
- The closure comes after the company already disclosed an interim complete response rate in the high 90% range with MRD-negativity in responders, raising the bar for what the mature dataset needs to confirm.
- AL amyloidosis has no approved CAR-T therapy and this trial is testing whether a cellular therapy already showing early complete responses can hold up on tolerability and durability through primary completion.
- The nearest approved cell therapies operate in multiple myeloma against a different target, leaving this trial without a direct same-mechanism, same-disease comparator to benchmark against.
The registry event
ClinicalTrials.gov records show NCT06097832, known as NEXICART-2, moved from Recruiting to Active, not recruiting on July 14, 2026, with its enrollment figure ticking up from 40 to 45 patients. The primary completion date holds at December 1, 2026, unchanged since an April 2024 amendment pushed it out one year from an original December 2025 target. The trial has logged two prior status changes and one primary-completion-date change since its October 2023 registration, a pace of amendment activity a protocol-stability read characterizes as stable. NCT06097832Study of NXC-201 CAR-T in Patients With Light Chain (AL) AmyloidosisNCT06097832
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial tests
NEXICART-2 is a Phase 1/2, open-label, single-arm study enrolling adults with relapsed or refractory AL amyloidosis who have received at least one prior line including a CD38 antibody and a proteasome inhibitor. Its four primary endpoints are treatment-related adverse events, adverse events graded by CTCAE v5.0, and confirmation of the maximum tolerated dose and recommended Phase 2 dose, the standard tolerability and dose-finding measures for an early-phase cell therapy trial. A single secondary endpoint tracks the percentage of patients with hematologic and organ response by consensus AL amyloidosis criteria. NCT06097832Study of NXC-201 CAR-T in Patients With Light Chain (AL) AmyloidosisNCT06097832
The interim signal
Before this enrollment closure, an interim analysis of NEXICART-2 reported a complete response rate of 95%, or 19 of 20 evaluable patients, along with MRD-negativity conversions in all four MRD-evaluable responders and no relapses observed at the time of reporting. That interim result, disclosed in May 2026, is what makes the trial's move to full enrollment and its approach to primary completion consequential: the mature dataset at 45 patients will show whether the complete response rate and MRD-negativity pattern hold as the safety database matures over the full 24-month adverse-event window specified in the protocol. NCT06097832Study of NXC-201 CAR-T in Patients With Light Chain (AL) AmyloidosisNCT06097832
Regulatory backdrop
NXC-201 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, and Orphan Drug designations from the FDA for relapsed/refractory AL amyloidosis. These designations reflect the agency's recognition of unmet need in the disease and can accelerate FDA interaction, but they carry no signal on whether the trial's data will support approval.
Competitive landscape
No CAR-T therapy is approved specifically for AL amyloidosis, and the nearest cell-therapy precedents, ciltacabtagene autoleucel and idecabtagene vicleucel, are approved in multiple myeloma against the BCMA target rather than in this disease. The broader AL amyloidosis and amyloidosis field remains mechanistically split: transthyretin-amyloidosis programs from Alnylam and BridgeBio use RNA-targeting or stabilizer approaches unrelated to cellular therapy, and the only other CAR-T program identified in AL amyloidosis is a Phase 1b/2 CD19/BCMA-directed study from Alexion still recruiting. With no validated cell-therapy mechanism established in this disease, a complete response rate that persists through the full safety follow-up window, without new tolerability signals emerging as more patients accrue, would be the result that distinguishes this program in a field where no comparator yet holds that precedent.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.